PLK1 interacts with Rap1GAP and phosphorylates it at Ser525.

<p>(A) 293T cells were co-transfected with Flag-Rap1GAP and Myc-PLK1 constructs. Cell lysates were prepared and subjected to immunoprecipitation with Flag or Myc antibodies, respectively. The immunoprecipitates were immunoblotted with anti-Flag and anti-Myc antibodies, respectively. (B) Endogenous Rap1GAP interacts with endogenous PLK1 in HeLa Cells. HeLa cells were synchronized by double thymidine block followed by release into nocodazole-containing media for 10 h. HeLa cells lysates were incubated with protein A/G sepharose conjugated with either control IgG or Rap1GAP antibody. The immunoprecipitates were immunoblotted with Rap1GAP or PLK1 antibodies, respectively. (C) Rap1GAP contains two PLK1 Polo box domain recognition motifs (S-S-P) located in the C-terminal sequence. (D) 293T cells were co-transfected with Myc-PLK1 and Flag-Rap1GAP (WT, S542A/P543A or S625A/P626A) (<i>left panel)</i>, or HA-Rap1GAP (WT, S484A or S525/529A) constructs (<i>right panel</i>). Cell lysates were prepared and subjected to immunoprecipitation with Myc antibody. The immunoprecipitates were immunoblotted with anti-Flag and anti-HA antibodies, respectively. (E) Recombinant GST-Rap1GAP wild type or SA mutants (S525A, S529A and S525/529A) were phosphorylated by purified recombinant PLK1 wild type or kinase dead mutant (KD). Visualization by autoradiography (<i>top panel</i>) revealed Rap1GAP phosphorylation by PLK1. Coomasie brilliant blue staining (<i>bottom panel</i>) protein bands for Rap1GAP and PLK1.</p

Rap1GAP degradation is required for cell proliferation.

<p>(A) HeLa cells were transiently transfected with two Rap1GAP-specific siRNAs or control siRNA. At 48 h after transfection, cell lysates were subjected to immunoblotting with Rap1GAP antibody. (B) The cell cycle profile of Rap1GAP-knocked down HeLa cells were assayed by FACS with propidium iodine staining. (C and D) The proliferative capacity of Rap1GAP-knocked down or overexpressed HeLa (C) or U2OS (D) cells was measured by BrdU ELISA assay. HeLa cells or U2OS cells were transfected with Flag-Rap1GAP WT, S525/529A mutant or control constructs, the cell proliferative capacity were measured by BrdU ELISA assay. Similar ELISA assay was performed when Rap1GAP was knocked down. (E and F) HeLa (E) or U2OS (F) cells were transfected with Flag-Rap1GAP WT, S525/529A mutant or control constructs respectively and selected with G418 for 3 weeks and outgrowth colonies were stained by crystal violet. Representative photographs of cell colonies were shown. Total numbers of the colonies from three independent experiments were counted. *P<0.05; **, p<0.001.</p

Rap1GAP is ubiquitinated and degraded in a β-TrCP dependent manner.

<p>(A) 293T cells were co-transfected with Flag-Rap1GAP and the indicated Myc-tagged E3 ligases constructs (β-TrCP1, SKP2, Cdc20, Cdh1 and Fbw5). At 24 h after transfection, cells were harvested and lysed. Cell lysates were subjected to immunoprecipitation with anti-Myc antibody. The immunoprecipitates were immunoblotted with anti-Flag and anti-Myc antibodies, respectively. (B) 293T cells were co-transfected with HA-Rap1GAP and Flag- β-TrCP1/2 constructs. Cell lysates were prepared and subjected to immunoprecipitation with anti-HA or anti-Flag antibodies, respectively. (C) Endogenous Rap1GAP interacts with endogenous β-TrCP in HeLa cells. At the 4 h before harvesting, cells were treated with the proteasome inhibitor, MG132. HeLa cell lysates were incubated with protein A/G sepharose conjugated with either control IgG or Rap1GAP antibody. The immunoprecipitates were immunoblotted with Rap1GAP or β-TrCP antibodies, respectively. (D) Alignment of amino acids corresponding to the DSGxxS sequence with Rap1GAP1 orthologs and other β-TrCP substrates. (E) 293T cells were co-transfected with Flag-β-TrCP1/2 and wild type HA-Rap1GAP or SA mutant (S525A, S529A and S525/529A) constructs. At 24 h after transfection, cells were harvested and lysed. Cell lysates were subjected to immunoprecipitation with anti-HA antibody. The immunoprecipitates were immunoblotted with anti-Flag and anti-HA antibodies, respectively. (F) Flag-Rap1GAP (WT or S525/529A), HA-ubiquitin, and β-TrCP1 (WT or ΔF Box mutant) constructs were co-transfected into 293T cells. Rap1GAP proteins were immunoprecipitated by anti-Flag antibody. The polyubiquitinated forms of Rap1GAP were immunoblotted with anti-HA antibody. (G) Control siRNA or β-TrCP-specific siRNA were transfected in HeLa cells that were synchronized by double thymidine block followed by release into nocodazole-containing media for the indicated times. Cell lysates were subjected immunoblotting with the indicated antibodies. (H) Flag-Rap1GAP wild type or S525/529A mutant was transfected into HeLa cells that were synchronized by double thymidine block followed by release into nocodazole-containing media for the indicated times. Cell lysates were subjected to immunoblotting with the indicated antibodies.</p

Rap1GAP is degraded during mitosis.

<p>(A and B) HeLa cells were synchronized by double thymidine block followed by release into nocodazole-containing media and harvested at the indicated times. Cell cycle profile was assayed by FACS with propidium iodine staining (A). Protein levels were analyzed by immunoblotting (B). (C) Nocodazole-arrested HeLa cells were released into fresh medium, and the Rap1GAP status was monitored at indicated times. (D) HeLa cells were arrested using nocodazole at the indicated times, and 20 µM MG132 was added during the last 4 h of the nocodazole treatment before the cells were harvested. (E) HeLa cells or U2OS cells were treated with 20 µM MG132 and harvested at the indicated times. Protein levels were examined by immunoblotting. (F) HeLa cells that were synchronized by double thymidine block followed by release into nocodazole-containing media, and harvested at 22 h. The cell lysates were incubated with or without λ-phosphatase (λ-PPase). The phosphorylation state of Rap1GAP was analyzed by immunoblotting.</p

PLK1 is essential for Rap1GAP degradation in mitosis.

<p>(A) Control siRNA or PLK1-specific siRNA was transfected in Hela cells that were synchronized by double thymidine block followed by release into nocodazole-containing media for the indicated times. Cell lysates were subjected immunoblotting with the indicated antibodies. (B) HeLa cells were synchronized by double thymidine block followed by release into nocodazole-containing media for 15 h, then the cells were treated with the PLK1-specific inhibitor GW843682X (10 µM), GSK3β-specific inhibitor LiCl (10 mM), or control (DMSO) for indicated times, Cell lysates were subjected to immunoblotting with the indicated antibodies. (C) Flag-tagged Rap1GAP wild type or mutants (S484A, S625A/P626A) were transfected into HeLa cells that were synchronized by double thymidine block followed by release into nocodazole-containing media for the indicated times. Cell lysates were subjected to immunoblotting with the indicated antibodies.</p

Sp1-binding sites mutations abrogate the repression of RLIM promoter by p53.

<p>(<b>A</b>) Schematic representation of the RLIM promoter luciferase reporter construct NP500-Luc and various mutated constructs with the Sp1 binding sites mutations (NP500-M1 to NP500-M1234). The four Sp1 binding sites S1 to S4 (wild type denoted as □ and mutations denoted a ▪) are shown. The sequences of the Sp1 binding sites are shown in the lower panel with the mutated sites underlined. (<b>B–D</b>) Cotransfection was performed as described in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0062832#pone-0062832-g005" target="_blank">Figure. 5B</a> using NP500-Luc and various mutated constructs with indicated Sp1-binding sites mutations, respectively. Luciferase assays were performed as described above. (<b>E</b>) EMSA analysis of the binding of Sp1 to RLIM promoter with different Sp1 binding site mutations (M1–M4). EMSA was performed as described in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0062832#pone-0062832-g003" target="_blank">Figure. 3D</a>. Lane 1: rhSp1+Biotin-labeled probes containing wild type Sp1-1 binding site +50-fold excess cold unlabeled competitor DNA. Lane 2: rhSp1+Biotin-labeled probes containing wild type Sp1-1 binding site. Lane 3: biotin-labeled probes containing wild type Sp1-1 binding site only. Lanes 4, 6, 8: rhSp1+Biotin-labeled probes containing mutant Sp1 binding site. Lanes 5, 7, 9: Biotin-labeled probes containing mutant Sp1 binding site only.</p

p53 represses RLIM at both mRNA and protein levels.

<p>(<b>A</b>) U2-OS cells were treated with 20 µM etoposide for the indicated period (0, 6 and 12 h) to induce the expression of endogenous p53. Cells were harvested for total RNA isolation followed by qPCR using primers specific for RLIM, p21, p53 and β-actin mRNA, respectively. (<b>B</b>) U2-OS cells were transfected with 20 µM p53 siRNA or 20 µM NS (non-specific) siRNA as control. RNA isolation and qPCR were performed as described above. (<b>C</b>) U2-OS or Hep3B cells were transfected with increasing amounts of p53 and harvested 24 h after transfection. Cells were harvested for total RNA isolation followed by qPCR using primers specific for RLIM and β-actin respectively. (<b>D</b>) U2-OS cells were treated with 20 µM etoposide for the indicated period (0, 6 and 12 h) to induce the expression of endogenous p53. Cells lysates were immunoblotted with antibodies to p53, RLIM and β-actin. (<b>E</b>) U2-OS or (<b>F</b>) Hep3B cells were transfected with different amount of plasmids encoding p53. Cells were harvested 40 h after transfection and lysates were immunoblotted with antibodies to p53, RLIM and β-actin.</p

p53 inhibits Sp1-mediated activation of the RLIM promoter.

<p>(<b>A</b>) Sp1 activated the RLIM promoter activity. H1299 cells were cotransfected with 100 ng of NP500-Luc with either 160 ng pCMV empty vector as control or increasing amounts (0, 10, 20, 40, 80 and 160 ng) of pCMV-Myc-Sp1 plasmid. The total amount of plasmid in each transfection was adjusted to be the same using the empty vector. Cells were harvested 30 h after transfection and lysed for measuring luciferase activity. (<b>B</b>) p53 inhibits Sp1-stimulated activity of the RLIM luciferase reporter. H1299 cells were cotransfected with 100 ng of NP500-Luc and increasing amounts (0, 1, 2.5, 5 and 10 ng) of pCMV-HA-p53 plasmid in the presence of a fixed amount (160 ng) of pCMV-Myc-Sp1 plasmid. H1299 cells were transfected with 100 ng NP500-Luc alone as control. Cell lysates were used for luciferase assays as described above. (<b>C</b>) p53 mutants can not inhibit Sp1-stimulated activity of the RLIM luciferase reporter. The indicated p53 wild type or mutant constructs were cotransfected with 100 ng of RLIM promoter reporter construct NP500-Luc and 160 ng pCMV-Myc-Sp1 plasmid. Cells were harvested 30 h after transfection and the cell lysates were prepared and used for luciferase assays as described above.</p

Le Courrier

16 mai 18501850/05/16 (N136)

Le Courrier

18 septembre 18371837/09/18 (N261)